Acquisition of Technology - Additional Information (Detail) (USD $)	1 Months Ended	86 Months Ended		3 Months Ended			3 Months Ended
	Jun. 30, 2007	Mar. 31, 2014	May 31, 2014 Scenario Forecast [Member] Questcor [Member] Patents [Member]	Mar. 31, 2014 Development Target One [Member] Questcor [Member] Patents [Member]	May 31, 2014 Development Target One [Member] Scenario Forecast [Member] Questcor [Member] Patents [Member]	May 31, 2014 Development Target One, Two and Three [Member] Scenario Forecast [Member] Questcor [Member] Patents [Member]	Mar. 31, 2014 Development Target Two [Member] Questcor [Member] Patents [Member]	Mar. 31, 2014 Development Target Three [Member] Questcor [Member] Patents [Member]	Mar. 31, 2014 Development Target Four [Member] Questcor [Member] Patents [Member]
Business Acquisition, Contingent Consideration [Line Items]
Upfront payment expensed as in-process research and development	$ 650,000	$ 650,000
Milestone payments, pegged to development targets					500,000	4,500,000	1,500,000	3,000,000	47,000,000
Development targets description				Upon the initiation of the first patient dosing in its Phase 3 clinical trial for EVK-001			Upon the FDA's acceptance for review of a new drug application for EVK-001	Upon the FDA's approval of EVK-001	Depend on EVK-001's commercial success and will only apply if EVK-001 receives regulatory approval. In addition, the Company will be required to pay to Questcor a low single digit royalty on net sales of EVK-001.
Milestone payments			$ 51,500,000
Expected expiration of patent right									2030